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Abstract
Background: Huang Lian Jie Du Decoction (HLJDD), a very famous traditional Chinese medicinal prescription, has
been used for heat dissipation and detoxification in China. This study was aimed to evaluate the reno-protective
effects of HLJDD against lupus nephritis (LN) in vivo in MRL/lpr mice.
Methods: Animals were administered orally every day for eight consecutive weeks except the mice of normal
group and model group. Organ indexes, serum interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-gamma (IFN-γ)
and the anti-double stranded DNA (anti-dsDNA) antibody were tested, respectively. Creatinine (Cr), blood urea
nitrogen (BUN) and urine protein were measured for renal function evaluation. The expression of phosphorylated
signal transducer and activator of transcription 3 (p-STAT 3) in kidney tissue was observed by western blot (WB)
and immunohistochemical (IHC) method. Meanwhile, histopathological changes in the renal were studied by
hematoxylin-eosin (H&E) staining.
Results: The mice of HLJDD-treated group exhibited a significant reduced mortality (p < 0.05), serum anti-dsDNA
level (p < 0.05) and renal immune complex deposition (p < 0.05), compared with the untreated MRL/lpr mice.
In addition, HLJDD treatment remarkably reduced the levels of BUN, Cr, proteinuria (p < 0.01) and the levels of
inflammatory cytokines such as IL-6, IL-10 and IFN-γ (p < 0.01). Moreover, HLJDD significantly suppressed the
phosphorylations of STAT 3 (p < 0.05) and the renal pathological changes.
Conclusions: The study implied that HLJDD may be a potential agent for the therapy of LN, and the down-regulated
p-STAT 3 expression suggesting that it may be one of the LN therapy targets for HLJDD.
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Background
Systemic lupus erythematosus (SLE) is a chronic multi-
system autoimmune disease with the features of antinu-
clear antibody in serum and pathological changes in
multiple organs, such as arthritis, nephritis and rash
[1, 2]. The symptoms of SLE are mostly displayed in
females with the ages of 15–50, and affects more than
1 million individuals each year [1, 3]. Immune complex
deposition, recruitment of neutrophils and complement
activation is the main reason for the pathogenesis of
SLE [1, 4].
Lupus nephritis (LN), one of the higher frequency
complications in SLE, is characterized by glomerulo-
nephritis and tubule-interstitial inflammation combined
with the depositing of immune complexes in the tissue
of renal [5–8]. The involvement of LN, especially the
type of proliferative glomerulonephritis significantly
decreased the LN patients life expectancy and their
survival [9]. Recently, the prognosis of SLE patients with
nephropathy has been markedly improved by the therapy
of immunosuppressive. However, the definite strategies
for LN treatment remain undefined, and there is still
many of patients progress to the end-stage renal disease
[8, 10, 11]. Thus, developing an inexpensive natural agents
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that possesses the protective effects for LN patients is
further a higher challenge.
Traditional Chinese medicine (TCM) has been widely
used in the treatment of many complex and refractory
diseases for thousands of years. Huang Lian Jie Du
Decoction (HLJDD), named Hwangryun-Hae-Dok Deco-
tion in Japan, is a very recognized traditional Chinese
medicinal prescription, mainly used to heat dissipation
and detoxification in China for 2000 years. This classical
formulation was first described in details in a famous
treatise “Wai Tai Mi Yao” by Wang Tao in the Tang
Dynasty, and which has been officially listed in Chinese
Pharmacopoeia (2005 edition) in the clinical practice of
TCM [12]. The decoction consists of four famous trad-
itional Chinese medicinal herbs, namely Huanglian
(Coptis chinensis Franch, Ranunculaceae) (HL), Huangqin
(Scutellaria baicalensis Georgi, Labiatae) (HQ), Huangbai
(Phellodendron amurense Rupr, Rutaceae) (HB) and Zhizi
(Gardenia jasminoides Ellis, Rubiaceae) (ZZ) in a weight
ratio of 3:2:2:3 [13]. In terms of TCM theory, HL used as
the major component aimed to balance the body dishar-
mony, HQ acted as the minister component to assist the
therapeutic action of the principal medicinal components.
The adjuvant and messenger constituent mainly used as
the guider to adjust the formulation to the targeted organs
or to eliminate the body disharmony caused by other
medicines [14]. In HLJDD, HB is classified as adjuvant
component and ZZ played both adjuvant and messenger
components. The combined effect of HB and ZZ is pur-
posed to directly resolving heat toxin in TCM theory [15].
Currently, HLJDD has attracted lots of attentions in
China and other Asia countries because of its potential
therapeutic effect in many diseases. Modern pharma-
cological works displayed that HLJDD possesses widely
effects, including the treatment of inflammation [16, 17],
gastrointestinal disorders [18], diabetes [17], vasodilation
[19], acute liver injury [20], Alzheimer disease [21, 22],
hypertension [23], multiple myeloma [24] and other car-
diovascular diseases [25, 26]. Until now, some research
had reported the content determinations of the main
bioactive components contained in HLJDD, in order to
understand and elucidate its pharmacological effects
and the relevant mechanisms [27, 28]. While, berberine,
baicalin, baicalein, wogonoside, wogonin and geniposide
have been identified, and been considered as the main bio-
active components in HLJDD [27, 29]. In those identified
components, berberine and baicalin have been reported
to possess anti-inflammatory effects and have been
used to treat many diseases [30]. Ni et al. reported that
the berberine exhibited a strong renoprotective effects in
in vivo diabetic nephropathy model [31]. Baicalin, a
flavonoid glycoside isolated from Scutellaria baica-
lensis, showed many biological activities, such as anti-
inflammatory [32], immune system modulatory activities
[33] and especially great for the protective effect on lead-
induced renal oxidative damage in mice [34]. Further-
more, the other main components of HLJDD are mainly
exhibited strong anti-inflammation, immune modulatory
and protective kidney effect [35–38]. In addition, HLJDD
exhibited the impressive anti-inflammatory effect in mice
through multi-target and multi-channel actions, due to its
multiple constituents (e.g. geniposide, baicalin, berberine,
palmatine etc.) in its decoction [17]. And the previous
published papers showed that HLJDD exerted beneficial
effects on the inflammation model of lipopolysaccharide-
induced RAW264.7 cells in vitro [17]. In addition, our
preliminary work displayed that HLJDD could reduce the
incidence of acute kidney injury, protect the kidneys and
regulating organs recovery in in vivo animal model.
With that in mind, our study was played to investigate
the potential protective effects by HLJDD with reduces
renal pathology and suppresses inflammation reaction in
LN MRL/lpr mice. To the best of our knowledge, there
is no any previous researches on the reno-protective
effects of HLJDD for LN treatment in vivo. This study also




The specific mouse enzyme-linked immunosorbent assay
(ELISA) kits of IL-6 (KMC0061) and IL-10 (KMC0101)
were obtained from Life Technologies, USA. IFN-γ
(SEA049Mu) commercial detection kit was purchased
from Cloud-Clone corp., USA. Serum BUN (C013-2) and
Cr (C011-2) were purchased from Nanjing Jiancheng
Bioengineering Institute, Jiangsu, China. BCA protein
assay kit was obtained from Zhongshan Institute of
Biotechnology, Beijing, China. Carboxymethyl cellulose
sodium salt (CMC-Na, C4888) was purchased from Sigma-
Aldrich, USA. All other reagents used in these experiments
were purchased from Sigma-Aldrich unless otherwise noted.
Prednisone acetate tablet (5 mg prednisone acetate per
tablet) was provided by Beijing Union Pharmaceutical
Company.
Herbal informations and preparation methods of HLJDD
The four crude herbal materials of HLJDD, Rhizoma
Coptidis (HL), Radix Scutellariae Baicalensis (HQ),
Cortex Phellodendri Amurensis (HB) and Fructus
Gardeniae (ZZ) were purchased from E-fong Pharma-
ceutical Company (Foshan, China) and authenticated
by professor Xiaoli Nie (School of Traditional Chinese
Medicine & Department of Traditional Chinese Medicine,
Nanfang Hospital, SouthernMedical University Guangzhou,
China) and Qi Xue (Department of General Surgery,
NanfangHospital, SouthernMedical University, Guangzhou,
China). The voucher specimens, deposited at the School of
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Traditional Chinese Medicine, Southern Medical University,
were 20150101-HL, 20150102-HQ, 20150103-HB and 2015
0104-ZZ for Rhizoma Coptidis, Radix Scutellariae, Cortex
Phellodendri and Fructus Gardeniae, respectively.
Briefly, to prepare the HLJDD, four dried crude herbs
were ground into powders, mixed in a weight ratio of
3:2:2:3 (HL:HQ:HB:ZZ, reaching a total weight of 1000 g)
and extracted twice with boiling water (1:10 and then
1:8, w/v) for 1.5 h. The aqueous extract were combined,
concentrated and vacuumized to dryness to afford
285.50 g HLJDD extract (yield: 28.55 %) [13], and then
stored in refrigerator at 4 °C. Suspension solution of the
extract was made in 0.25 % CMC-Na solution before
intragastric administration.
Animals
Ten weeks old female MRL/lpr mice (23.5 ± 2.0 g) and
sex- and age-matched WT C57BL/6 mice (21.5 ± 1.0 g)
were purchased from the Model Animal Research
Center of Southern Medical University (Guangzhou,
China). Mice were fed under specific pathogen-free
conditions at 24 ± 1 °C and 50 ± 5 % relative humidity
with a 12 h light/dark cycle and with free access to
standard water and food adlibitum. All the animals were
housed for 1 week under the controlled conditions before
experiments. All procedures involving mice in this manu-
script were approved by the Committee on the Ethics of
Animal Experiments of Southern Medical University
(SMU, Protocol Number: 2015063) and were carried
out in accordance with the National Institute of Health
guidelines (National Research Council of USA, 1996).
Experimental design
After 1 week acclimatization, twelve WT C57BL/6 mice
were used as group A: vehical group (10 ml/kg, 0.9 %
saline). And 48 MRL/lpr mice were randomly divided
into 4 groups (n = 12), including group B: model group
(10 ml/kg, 0.9 % saline), group C: HLJDD group (5.4 g/kg,
weight ratio between crude drug and rat), group D:
HLJDD+ prednisone group (5.4 g/kg HLJDD extract
+12.5 mg/kg prednisone) and group E: prednisone group
(12.5 mg/kg), each experimental group consisted of
12 mice. In addition, the dose of the drug used in the
experimental mice was converted by the conversion
coefficients table for the dose per kilogram of animal
and human body weight [39]. The above groups con-
tinuous administration of 8 weeks by gavage with the
same volumes (10 ml/kg/day).
All mice were sacrificed by cervical dislocation on the
day after the last intragastric administration. The amount
of 24 h proteinuria were assessed at weeks of 0, 4 and 8
respectively. Blood and renal tissue samples were collected
for further examinations. Serum was obtained by the
centrifuge at 3000 rpm for 10 min under 4 °C, and stored
at −20 °C before use. Renal tissues were obtained and
fixed in 4 % neutral-buffered formalin and embedded in
paraffin for histopathological and IHC analysis. Additional
renal samples were frozen in liquid nitrogen and stored at
−80 °C for biochemical assays. The experimental protocols
used in the present study were approved by the Animal
Ethical Committee of Southern Medical University.
Measurement of survival rate and animal general
information
The survival rate and the general animal information
including animal body weight, skin fur condition, the
appearances and behaviors of the animal in each group
were recorded at every week during the experiment time.
Measurement of renal function
Blood serum BUN and Cr levels were measured at
8 weeks using the commercial kit (Nanjing Jiancheng
Bioengineering Institute, Jiangsu, China) in an Olympus
AU 600 Autoanalyzer, Japan. The observation absor-
bance of BUN and Cr were read at 510 nm and the
content was calculated as mg/dL.
Measurement of the urinary protein
Urine samples were obtained using metabolic cages in 0,
4 and 8 weeks at 24 h during the whole experiment
period before sacrifice respectively. The collected urine
samples were centrifuged at 3000 rpm, 5 min to remove
all the particulates, then the supernatant was collected
and frozen at −20 °C before use. Urinary protein at 24 h
was measured by BCA protein assay kit (Zhongshan
Institute of Biotechnology, Beijing, China).
Measurement of inflammatory cytokines in circumference
blood
Serum IL-6, IL-10 and IFN-γ were detected by using
commercial ELISA kits based on the manufacturer’s
instructions. Optical density was measured with an
ELISA plate scanner at 450 nm (BioTek Elx × 808, BioTek,
USA).
Measurement of serum anti-dsDNA antibody and
complement C3 levels
The levels of anti-dsDNA antibodies in serum was deter-
mined by ELISA [40], according to the manufacturer’s
protocol. Briefly, 5 μg/mL calf thymus dsDNA (Sigma-
Aldrich, USA) first pre-coat into 96-well plates, and then
add the serum into 96-well plates, the absorbance was
measured at 450 nm. Mouse anti-dsDNA monoclone
antibody (Chemicon International, USA) was utilized to
prepare a reference standard curve, and the anti-dsDNA
concentrations were quantified by the standard curve.
Normal mouse IgG was considered as negative control.
The complement C3 in serum were determined using
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appropriate commercial ELISA kits (eBioscience, USA)
following the manufacturer’s protocols. The absorbance
of each sample was read at 450 nm with a microplate
spectrophotometer (BioTek Elx × 808, BioTek, USA).
Histopathological observation
For microscopic examination, mice renal specimens were
fixed with 4 % formaldehyde in 0.01 mol/L phosphate
buffer (pH 7.2) and embedding in paraffin, cut into 5 μm
thick sections, then stained with H&E and imaged under
a light microscope for routine histopathological examin-
ation. The examination of renal pathology was performed
in a blinded fashion by a pathologist.
Immunohistochemistry analysis
For IHC analysis, formalin-fixed and paraffin-embedded
renal sections (5 μm) were mounted on glass slides, then
deparaffinized, incubated in 3 % H2O2, 10 min to quench
endogenous peroxidase activity. Then use normal goat
serum to block 20 min, and incubated with monoclonal
mouse p-STAT 3 antibody (Cell Signaling Technology,
1:100 dilution) overnight at 4 °C. After that, then use the
second antibody horseradish peroxidase-conjugated goat
anti-mouse antibody (Abmart, 1:500 dilution) to incubate
30 min at 37 °C. The biding sites of the antibody could be
visualized after incubation with DAB at room temperature
(RT) for 10 min. Images were obtained at original magni-
fication of 400× (Olympus BX-51 Microscope, Japan).
The cells of renal tissue containing yellow granulation
in the endochylema or nucleus were regarded as positive
staining. The positive cell numbers were counted with
Q500IW image analysis system (BX-51 Olympus, Japan)
and Image-Pro Plus v 6.0 software (Media Cyberne tics
Inc., Bethesda, MD, USA).
Western blot analysis
For WB analysis, aliquot the total renal homogenate
from each animals were diluted in lysis buffer, which
contained the component of 150 mM NaCl, 50 mM
Tris–HCl, pH 7.4, 0.1 % SDS, 1 % Triton X-100, 0.1 mM
EGTA, 2 mM EDTA, 5 mM NaF, 1 mM Na3VO4, 5 mM
Na2PO4 and 1 × proteinase inhibitor cocktail (Roche,
USA), to a final protein concentration of 2 mg/mL.
Equal protein content (30 μg) were separated by SDS-
PAGE and transferred to PVDF membrane (Millipore,
USA). Membranes were incubated with primary anti-
body anti-p-STAT 3 (1:100) at 4 °C overnight, after RT
blocking with 5 % non-fat milk in TBST solution (TBS +
0.1 % Tween-20, pH 7.4) for 2 h. Then, washed the
membranes 3 times and incubated with HRP-conjugated
secondary antibody at RT for 2 h. Anti-β-actin antibody
(SantaCruz, USA) was used as internal controls. The
bands were visualized after an enhanced chemi-lumine
scence system (ECL) (Thermo, USA) incubation and
semi-quantitated with Image J software (Bio-Rad, USA).
The data are expressed as fold changes, normalize to the
internal control.
Statistical analysis
All data were expressed as mean ± S.D. (standard devi-
ation) and all statistical comparisons were analyzed by
means of a one-way ANOVA test followed by Dunett’s
t-test with SPSS 20.0 software. p < 0.01 was considered
as statistically significant.
Results
General observation and mortality of the experimental
mice
Hair loss and skin lesions with scab formation are very
common in MRL/lpr mice [41]. In the experiment, the
abnormal skin manifestation of MRL/lpr mice first
mainly displayed as red spots in head, neck, ears, tail
and back, and then became larger patches in two weeks,
finally changed to scab and fell off. Robust hair loss and
the severe damage of the ear skin and the tail were
observed in the model group. The group of HLJDD were
significantly reduced the skin lesions in MRL/lpr mice
with no red patches or spots, no skin fester and no
apparent hair loss. These preliminary results suggested
that HLJDD had a therapeutic effect in MRL/lpr mice.
Less activity was observed in the model group after
6 weeks, while all group mice behaved normally during
0–5 weeks. There were no significantly differences in body
weights among the groups of mice (Fig. 1a), although the
body weights of the model and drug-treatment groups
were lower than that of the control group by the end of
the study.
The effect of HLJDD on the mortality of MRL/lpr
mice was investigated. As expected, mortality was ob-
served in all groups except the control group. A signifi-
cant survival benefit was observed in HLJDD- and
HLJDD+ prednisone-treated MRL/lpr mice as compared
with the mice in the model group, and the group of
HLJDD combined prednisone exhibited the lowest death
rate (Fig. 1b). These results indicate that HLJDD signifi-
cantly increased the survival rate of MRL/lpr mice.
The effect of HLJDD on spleen coefficient
In MRL/lpr mice, the spleen weight could increase to
about 10 times larger than normal mice, which is one of
the most important indexes of SLE progression [42–44].
In the present study, spleen coefficients (organ weight/
body weight × 100 %) was significantly enlarged in the
model mice (p < 0.01, Fig. 2), compared to the normal
control mice. While HLJDD-treated group significantly
reduced the spleen coefficients, especially in HLJDD
combined prednisone group, compared to model group
(p < 0.01, Fig. 2).
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HLJDD treatment reduced 24 h proteinuria
Proteinuria is a major symptom to indicate the develop-
ment of renal disease in MRL/lpr mice. In order to
investigate the protective effect of HLJDD on the pro-
gression of renal disease, Urinary proteins in 24 h were
detected every 4 weeks during HLJDD-treated period
(from week 0 to 8). As presented in Fig. 3, the amount of
24 h proteinuria exhibited a progressive rise in the model
group, compared with C57BL/6 normal group (Fig. 3).
While the content of 24 h proteinuria was dramatically
decreased in HLJDD-treated groups at week 4, compared
with the model group (p < 0.01, Fig. 3). At week 8, mice
treated with HLJDD had markedly less 24 h proteinuria
than the model group mice (p < 0.01, Fig. 3). Obviously,
the content of 24 h proteinuria in HLJDD-treated mice fell
from 0.92 ± 0.25 g/24 h (week 0) to 0.30 ± 0.11 g/24 h
(week 8) (p < 0.01, Fig. 3), while in HLJDD combined
prednisone group, the content of 24 h proteinuria was
0.86 ± 0.18 g/24 h at week 0, and the number declined sig-
nificantly to 0.41 ± 0.11 g/24 h by week 4 and continued
to declined to 0.25 ± 0.09 g/24 h by week 8 (p < 0.01,
Fig. 3). Taken together, HLJDD demonstrated a significant
proteinuria reduction in the progression of SLE in MRL/
lpr mice with time-dependence.
The effect of HLJDD in renal function in MRL/lpr mice
The effect of HLJDD on renal function in MRL/lpr mice
was investigated. The level of serum BUN and Cr were
markedly increased in model group, compared to the
control groups (p < 0.01, Table 1). However, there was a
notable reduction in renal function in HLJDD-treated
MRL/lpr mice (p < 0.01, Table 1), especially in the HLJDD
combined prednisone group (p < 0.01, Table 1). While
prednisone-treated group also showed a significate de-
crease, compared to the model group (p < 0.01, Table 1).
All the data demonstrate that HLJDD improved the renal
function in MRL/lpr mice.
The effect of HLJDD on the serum inflammatory cytokines
Considering the important roles of inflammatory cyto-
kines in LN progress [45], the expression levels of serum
IL-6, IL-10 and IFN-γ were determined by ELISA. As
expected, the expression of serum IL-6, IL-10 and IFN-γ
were all significantly increased in the model group, com-
pared to the control group (p < 0.01, Table 2). However,
compared to the model group, HLJDD-treated group
was significantly reduced the expression levels of IL-6,
IL-10 and IFN-γ, respectively (p < 0.01, Table 2). As
similarly, there was also showed a significant difference
in prednisone-treated group (p < 0.01, Table 2). Further-
more, HLJDD combined prednisone group enhanced the
effect of HLJDD on LN, showed a remarkable decrease
in these three inflammatory cytokines, compared to the
model group (p < 0.01, Table 2).
A B 
Fig. 1 a The body weight of the experimental MRL/lpr mice. There is no significant difference in all experimental groups. b The survival
rate of the experimental MRL/lpr mice Values are presented as mean ± SD. #p < 0.05 versus control group, *p < 0.05 versus model group
Fig. 2 Spleen coefficient (organ weight/body weight × 100 %) of
the experimental MRL/lpr mice. Values are presented as mean ±
SD. ##p < 0.01 versus control group, **p < 0.01 versus model group
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The effect of HLJDD on the levels of anti-dsDNA antibody
and complement C3 in the serum
Autoantibody production is a sensitive clinical measure-
ment for SLE, which is closely related to LN activity
[46, 47], thus, the anti-dsDNA antibodies and the depo-
sition of C3 concentrations in serum were determined.
As shown in Fig. 4, anti-dsDNA antibody in serum was
not detected in C57BL/6 control group, which means
that there was no LN changes, whereas the anti-dsDNA
antibody levels in model group mice exhibited an obvious
evidence of LN (p < 0.01, Fig. 4). HLJDD decreased the
production of anti-dsDNA, especially in HLJDD com-
bined prednisone group (p < 0.05, Fig. 4). Furthermore,
compared to the control group, the levels of complement
C3 in serum in model mice were significantly decreased
(p < 0.01, Fig. 4). While the low levels of complement
C3 were recovered in HLJDD-treated mice, compared
to model group (p < 0.05, Fig. 4).
Histopathological studies
Furthermore, to assess inflammation in MRL/lpr mice,
H&E staining was used to detect the pathologic changes
of the tissue of kidneys at the end of the study. Mice in
the control group showed a clear and regular glomerular
architecture and cell structure of the kidneys (Fig. 5a),
while the model group mice exhibited a typical features
of renal disease, such as arterial wall destruction, mem-
brane proliferation and infiltration of inflammatory cells
(Fig. 5b). In contrast, compared to the model group, the
lesions in HLJDD treated mice were notably ameliorated
with less damage to glomeruli and less inflammatory cells
(Fig. 5c), which similar to prednisone group (Fig. 5e).
The effect of HLJDD on the expression of renal p-STAT 3
protein in MRL/lpr mice
Previous studies in both humans and lupus prone mouse
models have described that total levels of STAT 3 as well
Fig. 3 HLJDD reduced 24 h proteinuria in serum of MRL/lpr mice. Twenty-four hour urinary protein was detected by Coomassie Brilliant
Blue test at weeks 0, 4 and 8. Values are presented as mean ± SD. ** indicates p < 0.01
Table 1 Effect of HLJDD in renal function in MRL/lpr mice
Groups BUN (mg/dL) Cr (mg/dL)
Control 9.93 ± 1.02 9.14 ± 0.88
Model 20.66 ± 2.00## 18.22 ± 1.49##
HLJDD 12.18 ± 1.11** 11.81 ± 0.92**
HLJDD + Prednisone 10.56 ± 0.85** 10.02 ± 0.67**
Prednisone 13.75 ± 1.30** 12.39 ± 1.03**
Values represent the mean ± S.D. The one-way ANOVA was performed on the
raw data
##Significant difference at p < 0.01 levels compared with the control group
**Significant difference at p < 0.01 levels compared with the model group
Table 2 Effect of HLJDD on the serum inflammatory cytokines
Groups IL-6 (pg/mL) IL-10 (pg/mL) IFN-γ (pg/mL)
Control 18.96 ± 1.54 180.13 ± 6.33 0.65 ± 0.02
Model 78.55 ± 4.01## 642.57 ± 10.22## 18.23 ± 1.50##
HLJDD 34.75 ± 1.11** 211.33 ± 5.34** 1.28 ± 0.17**
HLJDD + Prednisone 34.36 ± 1.85** 201.08 ± 4.73** 1.12 ± 0.09**
Prednisone 35.11 ± 2.30** 222.45 ± 5.15** 1.44 ± 0.04**
Values represent the mean ± S.D. The one-way ANOVA was performed on the
raw data
##Significant difference at p < 0.01 levels compared with the control group
**Significant difference at p < 0.01 levels compared with the model group
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as the activation of STAT 3 are increased, compared
to the healthy controls [48, 49]. Thus, the activation
of p-STAT 3 were detected by the method of IHC
and WB in the study. In IHC stained kidney sections,
the expression of p-STAT 3 was observed mainly in
the mesangial cells, glomerular endothelial cells and some
renal tubular epithelial cells in MRL/lpr mice group
(Fig. 6A). While consistent with the IHC results, the
expression of p-STAT 3 protein was readily detected by
WB in the model group (Fig. 6C). Conversely, p-STAT 3
expression was evidently decreased in mice treated with
HLJDD (p < 0.01, p < 0.05, Fig. 6B, D), especially in the
group of HLJDD combined prednisone (p < 0.01, Fig. 6B,
D). Furthermore, IHC analysis also revealed that predni-
sone significantly restricted phosphorylation of STAT 3
compared to the model group (p < 0.05, Fig. 6B), though
WB analysis showed no significant inhibition (Fig. 6D).
These findings demonstrated that the expression of p-
STAT 3 was blocked in the group of HLJDD-treated mice,
which implying that STAT 3 may be one of the targets
for HLJDD in the treatment of LN.
Discussion
SLE is an autoimmune disease with the presence of
immune complexes by autoantibodies, and these immune
complexes would finally activating the complement
pathway, forming kidney depositions and leading to the
pathogenesis of LN [50]. Recently, although some immuno-
suppressive and anti-inflammatory agents such as steroid
hormones and cyclosporine A are used in clinic patient
for the prevention of SLE [51], there is no any common
accepted therapy to reverse or prevent this process in
humans, and the patients not only die from renal failure
but also die from the opportunistic infection and cancer
induced by the immunosuppression [43]. Thus, more and
more attentions have been paid to the research and the
development of effective therapy and agents for SLE dis-
eases. Furthermore, the animal model of MRL/lpr mice is
one of the commonly used spontaneous SLE models, and
the mice symptoms are similar to human SLE, including
immune complex-induced organ injury [52].
Chinese traditional herbal medicine is the natural
therapeutic agent that used under the guidance of trad-
itional Chinese medical theory, it has widely applied in
alternative or complementary therapies and became
more popular worldwide. Meanwhile, most herbal medi-
cines are usually prescribed in combination in clinical
application, in order to obtain the synergistic effects or
to reduce the possible side effects, which are difficult to
Western medicines [53]. HLJDD is a popular formula of
TCM, which consist of 4 herbs. Previous chemical ana-
lysis show that the main active components in HLJDD
Fig. 4 Effect of HLJDD on the levels of anti-dsDNA antibody and complement C3 in the serum. Values are presented as mean ± SD.
##p < 0.01 versus control group, **p < 0.01 versus model group
Fig. 5 The H&E (×400) of the kidney sections in MRL/lpr mice. a Control group; b Model group; c HLJDD group; d HLJDD + Prednisone
group; e Prednisone group
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including flavonoids, alkaloids and iridoids derived from
its 4 herbs, and HLJDD played a much more clear anti-
inflammatory effect as a whole prescription than that of
its 4 typical herbs [17]. Moreover, recent researches
also suggest that HLJDD exhibit immunity regulation,
anti-complementary, anti-tumor, anti-hypoglycemic and
anti-bacterial activities [54]. However, whether HLJDD
alleviate the LN damage is not clear now. Thus, in the
present study, we explored the reno-protective effects of
HLJDD on LN MRL/lpr mice. As our knowledge, it is the
first time to examine the effects of HLJDD on the therapy
of SLE.
The lupus-like renal disease is a major feature in LN
MRL/lpr mice [55], and the renal dysfunction could
initially lead to mice death in the late stage of LN [56].
Proteinuria, a biomarker of the kidney inflammation, is
an important cause for the mortality of MRL/lpr mice
model, it is reflect the progression of renal disease. In
the present study, HLJDD markedly increased the survival
rate of MRL/lpr mice and suppressed the progression of
proteinuria with more than 3-fold in the end of 8 weeks.
Meanwhile, HLJDD dramatically decreased the spleen
coefficient in MRL/lpr mice, which is one of the most
important indexes in SLE progression. Furthermore, the
kidney pathologic changes assessed by H&E staining
demonstrated that HLJDD obviously alleviated the renal
pathological injury, such as membrane proliferation,
inflammatory cell infiltration and arterial wall destruction.
The key pathogenesis of LN is the continued increase
in the autoantibodies productions and immune complex
depositions in kidney [47]. The serum anti-dsDNA
antibody levels is very specific for SLE [57], which is
remain widely utilized to help establish the diagnosis
of SLE and to predict nephritis activities [58]. While
immune complex deposition can trigger a series of events
that result in kidney inflammation and injury [59]. Our
study showed that treatment with HLJDD remarkably
reduced the serum levels of anti-dsDNA antibody and
renal immune complex deposition complement C3 in
MRL/lpr mice.
What’s more, an activated and dysregulated immune
response is the characterize of SLE, and the pathophy-
siology of this regulatory defect is leaded by a distorted
balance of regulatory cytokines. Thus, inflammation
plays an indispensable role in the progression of LN
[60, 61]. Recent reports showed that Th2 cytokines
IL-6 and IL-10 have been shown to be important in
the generation of SLE disease associated anti-dsDNA
antibodies [62, 63]. In addition, Th1 cytokines IFN-γ,
a potent immunomodulatory cytokine, is produced by
T cell and natural killer cell (NK cell). It is a member
of the interferon family that regulates the immune
Fig. 6 Effect of HLJDD on inhibiting phosphorylation of STAT 3 (p-STAT 3). a p-STAT 3 was measured on paraffin sections of the kidneys at
the end of 8 week by immunohistochemistry (×400): (a) Control group; (b) Model group; (c) HLJDD group; (d) HLJDD + Prednisone group;
(e) Prednisone group. b Mean density of p-STAT 3 was measured by Image-Pro Plus v 6.0. c Further analysis was to measure p-STAT 3
by Western blot. d Western blot of p-STAT 3 were subjected to semi-quantitative analysis by Image J. Values are presented as mean ± SD.
##p < 0.01 versus control group, **p < 0.01 versus model group, *p < 0.05 versus model group. Western blot were repeated > 3 times
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responses through activation of mononuclear macrophage,
lymphocyte and NK cell, which is plays an important role
in the pathogenesis of SLE [64]. The results in our study
showed that oral administration of HLJDD could signi-
ficantly inhibited the secretion of IL-6 and IL-10 in peri-
pheral blood, which is consistent with the anti-dsDNA
antibody levels. And the IFN-γ levels also remarkably
decreased in HLJDD-treated group, compared to the
model group.
STAT3, a transcription factor, is one of the member of
JAK/STAT signaling pathway. It is activated downstream
growth factors of a host, like the cytokines and chemo-
kines [65]. The receptor of the STAT 3 will be dimerization
and activation of Jak kinases, when its ligand bind to the
receptor, which will in turn activate and phosphorylate
STAT proteins. Then the phosphorylated STAT proteins
will translocate to the nucleus and mediate gene transcrip-
tion [66]. STAT 3 plays an important role in the develop-
ment of cancer, chronic inflammation such as hepatitis,
rheumatoid arthritis and etc. [67]. Several previous studies
described that the activated STAT 3 in aglomerular mainly
reside in diabetic nephropathy [68], kidney injury by HIV
[69] and chronic proliferating immune complex glomeru-
lonephritis [70]. In our study, compared to control group,
the expression of p-STAT 3 was dramatically increased.
While HLJDD-treated group significantly down-regulate
the expression of p-STAT 3 through IHC and WB analysis.
These results suggest that p-STAT 3 may be one of a
promising therapeutic target for LN.
Conclusion
Altogether, the study suggests that HLJDD has a potent
reno-protective activity in the LN MRL/lpr mice. The
treatment of HLJDD decreased the concentration of
proteinuria, improves renal function and mitigates the
renal pathology in LN. These effects followed by sup-
pressing activation of p-STAT 3, restraining release of
inflammatory cytokines, reducing autoimmune activity
and by inhibiting macrophage infiltration in the kidney of
LN MRL/lpr mice. Thus, HLJDD represents a potential
therapy in preventing the LN progress, which could be a
valuable alternative medicine for the effective treatment of
SLE disease. Furthermore, the study also provided a proof
of concept for the treatment of HLJDD in SLE disease.
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